Catalyst
Slingshot members are tracking this event:
AbbVie's HUMIRA (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ABBV | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 27, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Humira, Adalimumab, Chmp Positive Opinion, Non-infectious Uveitis, Visual Acuity, Corticosteroid
